Thrombolytic and newer mechanical device treatment for acute ischemic stroke

For 8 years, only intravenous tissue plasminogen activator was approved by the US FDA for acute stroke treatment. The US FDA has now cleared the Merci® Retriever (Concentric Medical, Inc.), a corkscrew-like device attached to a catheter, for the removal of clots causing ischemic strokes. Since the clearance was based on nonrandomized treatment trials, practitioners must scrutinize available data describing effects of the device on recanalization of the vessel, outcomes and important adverse events, such as symptomatic intracranial hemorrhage. This article reviews the study findings that are likely to contribute to current treatment decisions.

[1]  W. Smith,et al.  Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. , 2006, AJNR. American journal of neuroradiology.

[2]  J. Koziol.  NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.

[3]  C. Molina,et al.  Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator: Selecting Patients for Rescue Reperfusion Techniques , 2006, Stroke.

[4]  H. Lutsep,et al.  Safety and Efficacy of Mechanical Embolectomy in Acute Ischemic Stroke: Results of the MERCI Trial , 2005, Stroke.

[5]  Achim Gass,et al.  Transcranial Low-Frequency Ultrasound-Mediated Thrombolysis in Brain Ischemia: Increased Risk of Hemorrhage With Combined Ultrasound and Tissue Plasminogen Activator Results of a Phase II Clinical Trial , 2005, Stroke.

[6]  Michael D. Hill,et al.  Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study , 2005, Canadian Medical Association Journal.

[7]  À. Rovira,et al.  Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol , 2005, Stroke.

[8]  T. Brott,et al.  Approval of the MERCI clot retriever: a critical view. , 2005, Stroke.

[9]  Fernando Vinuela,et al.  MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia , 2004, Stroke.

[10]  A. Alexandrov,et al.  Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. , 2004, The New England journal of medicine.

[11]  Alexander Norbash,et al.  Mechanical Thrombolysis in Acute Ischemic Stroke With Endovascular Photoacoustic Recanalization , 2004, Stroke.

[12]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[13]  P. Heuschmann,et al.  Frequency of Thrombolytic Therapy in Patients With Acute Ischemic Stroke and the Risk of In-Hospital Mortality: The German Stroke Registers Study Group , 2003, Stroke.

[14]  R. Grubb,et al.  Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.

[15]  A. Weill,et al.  North American clinical experience with the EKOS MicroLysUS infusion catheter for the treatment of embolic stroke. , 2003, AJNR. American journal of neuroradiology.

[16]  A. Alexandrov,et al.  Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator , 2002, Neurology.

[17]  S. Dimauro,et al.  Cytochrome c oxidase deficiency due to a novel SCO2 mutation mimics Werdnig-Hoffmann disease. , 2002, Archives of neurology.

[18]  G. Albers,et al.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.

[19]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[20]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[21]  B. Tilley,et al.  Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. , 1997, Annals of emergency medicine.

[22]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[23]  T. N. t-P. S. S. Group,et al.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. , 1997, Stroke.